(Q40485362)

English

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

phase II clinical trial

0 references

0 references

0 references

renal carcinoma

1 reference

based on heuristic

inferred from title

author name string

Eric Winquist

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jennifer Knox

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jean-Pierre Ayoub

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Lori Wood

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Nancy Wainman

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gregory K Reid

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Laura Pearce

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Ajit Shah

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Elizabeth Eisenhauer

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

1 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

159-167

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-006-5938-1

0 references

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense therapy for cancer--the time of truth

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense oligonucleotide therapy in urology

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA methylation, nuclear structure, gene expression and cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16502349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for advanced renal cell cancer.

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425

Identifiers

10.1007/S10637-006-5938-1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40485362&oldid=2052684872"